Logo

Nanogen Submits Prototype of Rapid Flu Dx to CDC

Dec 10, 2007
NEW YORK (GenomeWeb News) - Nanogen has submitted an influenza diagnostic to the US Centers for Disease Control and Prevention for evaluation for further development, the company said today.
 
Nanogen said this submission fulfills a second-phase milestone requirement on a contract CDC awarded to Nanogen and its business partner, the San Francisco-based HX Diagnostics.
 
The company said it will continue to develop the point-of-care influenza diagnostic and will undertake clinical trials pending approval and funding from the CDC.
  
Around 36,000 people in the US die each year from influenza infections, the company said.
 
The CDC is concerned about the possibility of a deadly influenza subtype arising and causing a pandemic and is funding development of tests that can act as “sentinels” for potential outbreaks, Nanogen said.

Breaking News
The Scan

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.

Clinical Genomic Lab Survey Looks at Workforce Needs

Investigators use a survey approach in Genetics in Medicine Open to assess technologist applications, retention, and workforce gaps at molecular genetics and clinical cytogenetics labs in the US.

Study Considers Gene Regulatory Features Available by Sequence-Based Modeling

Investigators in Genome Biology set sequence-based models against observational and perturbation assay data, finding distal enhancer models lag behind promoter predictions.

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.